Emergent BioSolutions Inc
(NYSE:EBS)
$
10.68
-0.21 (-1.93%)
Market Cap: 578.69 Mil
Enterprise Value: 1.38 Bil
PE Ratio: 0
PB Ratio: 1.46
GF Score: 63/100 Emergent BioSolutions Inc at Goldman Sachs Leveraged Finance and Credit Conference Transcript
May 12, 2022 / 05:40PM GMT
Release Date Price:
$29.08
(+3.97%)
Franklin Jarman
Goldman Sachs Group, Inc., Research Division - VP & Senior Analyst
Okay. Well, thanks, everyone, for joining us. Our next panel is with Emergent BioSolutions. My name is Franklin Jarman. I'm a high yield health care analyst here and very excited to have Rich Lindahl, who is the EVP and CFO of the company; and Bob Burrows to his left, who is the Vice President of Investor Relations.
Questions & Answers
Franklin Jarman
Goldman Sachs Group, Inc., Research Division - VP & Senior Analyst
Maybe just to level set for everyone, I mean I think you guys have a fascinating business. And so I'd love to just maybe have you provide a little bit of an overview around the business model, some of your products and really how you think about the value proposition to the customer base overall.
Richard S. Lindahl
Emergent BioSolutions Inc. - Executive VP, CFO & Treasurer
Sure. Thank you, Frank, and thank you for having us here at the conference, and thank you all for taking the time to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot